SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
SEC Accession No. 0001213900-21-067430
Filing Date
2021-12-27
Accepted
2021-12-27 06:03:09
Documents
30
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 6-K ea153034-6ka1_biond.htm   iXBRL 6-K/A 19153
2 INTERIM FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 ea153034ex99-2_biondvax.htm   iXBRL EX-99.2 391724
  Complete submission text file 0001213900-21-067430.txt   1625917

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bvxv-20210930.xsd EX-101.SCH 27533
4 XBRL CALCULATION FILE bvxv-20210930_cal.xml EX-101.CAL 25575
5 XBRL DEFINITION FILE bvxv-20210930_def.xml EX-101.DEF 77263
6 XBRL LABEL FILE bvxv-20210930_lab.xml EX-101.LAB 179866
7 XBRL PRESENTATION FILE bvxv-20210930_pre.xml EX-101.PRE 82569
24 EXTRACTED XBRL INSTANCE DOCUMENT ea153034-6ka1_biond_htm.xml XML 134180
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K/A | Act: 34 | File No.: 001-37353 | Film No.: 211518828
SIC: 2836 Biological Products, (No Diagnostic Substances)